Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
Atherogenic index of plasma
Diabetes mellitus
Metabolic-associated fatty liver disease
Non-alcoholic fatty liver disease
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
11 Jul 2022
11 Jul 2022
Historique:
received:
17
12
2021
accepted:
17
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduce the risk of morbidity and mortality. This study investigated the association between the atherogenic index of plasma (AIP) and MAFLD in patients with T2D. A retrospective case-control study was conducted and medical records of patients with T2D were assessed. The baseline characteristics, anthropometric indices, laboratory measurements including liver functions tests, fasting blood sugar, HbA1C, lipid profile were documented. Out of 2547 patients with T2D, 824 (32.4%) had MAFLD. The multivariate logistic regression analysis showed a significant difference in female-to-male ratio (1.11 vs. 1.33, OR = 0.347, P-value < 0.001), ALT (42.5 ± 28.1 vs. 22.4 ± 11.1, OR = 1.057, P-value < 0.001), and AIP (0.6 ± 0.3 vs. 0.5 ± 0.3, OR = 5.057, P-value < 0.001) between MAFLD and non-MAFLD groups, respectively. According to the AIP quartile, the prevalence of MAFLD increased significantly in patients with higher AIP quartiles (P-value < 0.001). Also, we found a cut-off of 0.54 for AIP in predicting MAFLD in patients with T2D (sensitivity = 57.8%, specificity = 54.4%). In this study, we found that AIP is a good and independent predictor for MAFLD in patients with T2D which could help physicians in early diagnosis and follow-up of patients with T2D.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduce the risk of morbidity and mortality. This study investigated the association between the atherogenic index of plasma (AIP) and MAFLD in patients with T2D.
METHOD
METHODS
A retrospective case-control study was conducted and medical records of patients with T2D were assessed. The baseline characteristics, anthropometric indices, laboratory measurements including liver functions tests, fasting blood sugar, HbA1C, lipid profile were documented.
RESULTS
RESULTS
Out of 2547 patients with T2D, 824 (32.4%) had MAFLD. The multivariate logistic regression analysis showed a significant difference in female-to-male ratio (1.11 vs. 1.33, OR = 0.347, P-value < 0.001), ALT (42.5 ± 28.1 vs. 22.4 ± 11.1, OR = 1.057, P-value < 0.001), and AIP (0.6 ± 0.3 vs. 0.5 ± 0.3, OR = 5.057, P-value < 0.001) between MAFLD and non-MAFLD groups, respectively. According to the AIP quartile, the prevalence of MAFLD increased significantly in patients with higher AIP quartiles (P-value < 0.001). Also, we found a cut-off of 0.54 for AIP in predicting MAFLD in patients with T2D (sensitivity = 57.8%, specificity = 54.4%).
CONCLUSION
CONCLUSIONS
In this study, we found that AIP is a good and independent predictor for MAFLD in patients with T2D which could help physicians in early diagnosis and follow-up of patients with T2D.
Identifiants
pubmed: 35818084
doi: 10.1186/s40001-022-00731-x
pii: 10.1186/s40001-022-00731-x
pmc: PMC9275169
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Informations de copyright
© 2022. The Author(s).
Références
J Diabetes Res. 2016;2016:4370490
pubmed: 27965983
Medicine (Baltimore). 2016 Jun;95(24):e3866
pubmed: 27310971
Int J Endocrinol. 2018 Nov 29;2018:1765835
pubmed: 30627157
Clin Biochem. 2001 Oct;34(7):583-8
pubmed: 11738396
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Curr Vasc Pharmacol. 2018;16(6):589-595
pubmed: 29299987
Lipids Health Dis. 2020 Jun 23;19(1):148
pubmed: 32576204
Surg Infect (Larchmt). 2020 Feb;21(1):9-14
pubmed: 31369351
J Diabetes Complications. 2015 Nov-Dec;29(8):1240-7
pubmed: 26297218
Circulation. 2011 Nov 8;124(19):2056-64
pubmed: 21986289
J Gastroenterol Hepatol. 2018 Jan;33(1):70-85
pubmed: 28670712
J Res Med Sci. 2013 Feb;18(2):89-93
pubmed: 23914207
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Medicine (Baltimore). 2017 Sep;96(37):e8058
pubmed: 28906400
Metabolism. 2014 Dec;63(12):1469-79
pubmed: 25242435
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Nat Rev Nephrol. 2022 Apr;18(4):259-268
pubmed: 35013596
Curr Pharm Des. 2020;26(10):1045-1061
pubmed: 31738141
Lipids Health Dis. 2019 Sep 12;18(1):170
pubmed: 31511022
Diabetes Care. 2011 Aug;34(8):1869-74
pubmed: 21730284
Lipids Health Dis. 2019 Apr 13;18(1):99
pubmed: 30987629
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Circulation. 2014 Feb 4;129(5):570-9
pubmed: 24192801
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Obes Facts. 2016;9(2):65-90
pubmed: 27055256
Am J Cardiol. 2012 Jun 15;109(12):1749-53
pubmed: 22449634
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612
pubmed: 33972770
J Clin Med. 2022 Feb 12;11(4):
pubmed: 35207239
Endocr Pract. 2014 Dec;20(12):1249-57
pubmed: 25100370
Lipids Health Dis. 2018 Aug 22;17(1):197
pubmed: 30134981
Metabolism. 2022 Jan;126:154925
pubmed: 34740573
J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8
pubmed: 25885947
Diabetologia. 2015 May;58(5):886-99
pubmed: 25725623
Lipids Health Dis. 2018 Dec 13;17(1):284
pubmed: 30545385
Metabolism. 2016 Aug;65(8):1096-108
pubmed: 26856933